Clearside Biomedical, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Thorp Clay of Clearside Biomedical, Inc. (CLSD) acquired 15,000 shares of common stock at an average price of $0.92 on February 24, 2025, increasing their total holdings.
NASDAQ
Charles A. Deignan, CFO of Clearside Biomedical, Inc., acquired 200,000 employee stock options on January 8, 2025.
NASDAQ
Clearside Biomedical's Chief Medical Officer, Ngai Hang Victor Chong, was granted employee stock options to purchase 250,000 shares of common stock on January 8, 2025.
NASDAQ
Clearside Biomedical CEO George M. Lasezkay acquired 500,000 employee stock options on January 8, 2025, exercisable at $0.97 per share.
NASDAQ
Ngai Hang Victor Chong, Chief Medical Officer of Clearside Biomedical, reports acquiring 36,500 shares of common stock at $1 and disposing of 100,000 shares on November 1, 2024.
NASDAQ
Ngai Hang Victor Chong, Chief Medical Officer of Clearside Biomedical, recently purchased 23,500 shares of common stock at a price of $1.06 per share.
NASDAQ
Director Anthony S. Gibney acquired 45,000 stock options in Clearside Biomedical, Inc. on June 20, 2024, at an exercise price of $1.15.
NASDAQ
Director Benjamin R. Yerxa acquired stock options in Clearside Biomedical, Inc. on June 20, 2024.
NASDAQ
Director Nancy J. Hutson reported the acquisition of stock options in Clearside Biomedical, Inc. on June 20, 2024.
NASDAQ
Director Richard Croarkin acquired 45,000 stock options in Clearside Biomedical, Inc. on June 20, 2024.
NASDAQ
Director Jeffrey L. Edwards acquired 45,000 stock options in Clearside Biomedical, Inc. on June 20, 2024.
NASDAQ
William D. Humphries, a director of Clearside Biomedical, Inc., acquired stock options for 45,000 shares on June 20, 2024.
NASDAQ
Director Clay Thorp reports acquisition of stock options in Clearside Biomedical, Inc.
NASDAQ
Director Christy L. Shaffer acquired stock options in Clearside Biomedical, Inc. on June 20, 2024.
NASDAQ
Director Benjamin R. Yerxa purchased 7,813 shares of Clearside Biomedical, Inc. at $1.31 per share on May 15, 2024.
NASDAQ
Form 4: Clearside Biomedical Director Anthony Gibney S. Acquires 100,000 Shares in Open Market Purchases
Director Anthony Gibney S. of Clearside Biomedical, Inc. [CLSD] recently acquired 100,000 shares of common stock through open market purchases on April 17 and 18, 2024.
NASDAQ
Director Anthony Gibney acquired stock options in Clearside Biomedical, Inc. on April 15, 2024.
NASDAQ
Clearside Biomedical's Chief Medical Officer, Ngai Hang Victor Chong, purchased 30,000 shares of common stock at $1.60 per share on March 20, 2024.
NASDAQ
Ngai Hang Victor Chong, Chief Medical Officer of Clearside Biomedical, received stock options for 450,000 shares on March 18, 2024.